国产恩替卡韦治疗慢性乙型肝炎患者早期抗病毒疗效观察*

doi:10.3969/j.issn.1672-5069.2017.02.025

Abstract

Guo Lijie，Wang Yan，Wang Min，et al.. Domestic entecavir in treatment of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 226-227.

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）.实用肝脏病杂志，2016，19（3）：Ⅴ-ⅩⅩⅢ.
[2] European Association for the Study of the Liver．EASL clinical practice guidelines：management of chronic hepatitis B virus infection．J Hepatol，2012，57（1）：167-185.
[3] Peng CY，Chien RN，Liaw YF. Hepatitis B virus related decompensated liver cirrhosis:benefits of antiviral therapy. J Hepatol，2012，57（2）:442-450.
[4] 连佳，韩涛，向慧玲，等.恩替卡韦与阿德福韦酯单药治疗慢性乙型肝炎相关性肝病患者240周的随机对照研究. 中华肝脏病杂志，2015，23（10）：733-737.
[5] 朱其荣，李玲，梅小平.恩替卡韦分散片治疗慢性乙型病毒性肝炎慢加急性肝衰竭的近期疗效.广东医学，2016，37（8）：1218-1220.
[6] 常青山.恩替卡韦分散片与恩替卡韦片治疗乙型肝炎肝硬化的对比研究.中国医院用药评价与分析，2014，54（11）：990-992.
[7] 张建春，翁锡定，张菊花，等.恩替卡韦治疗慢性乙型肝炎临床观察.实用肝脏病杂志，2012，15（3）：261-262.
[8] 孟庆华，侯维.2015年版《慢性乙型肝炎防治指南》-慢性乙型肝炎抗病毒治疗指南解读.中国全科医学，2016，19（14）：1613-1615.
[9] 连佳，韩涛，向慧玲，等.恩替卡韦与阿德福韦酯单药治疗慢性乙型肝炎相关肝病患者240周的随机对照研究.中华肝脏病杂志，2015，23（10）：733-737.
[10] 柴艳云，李建国，张新龙.阿德福韦酯与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者临床疗效观察.实用肝脏病杂志，2014，17（3）：307-308.
[11] 崔振利，赵霞，张慧智.乙型肝炎肝硬化治疗中不同核苷类抗病毒药物的应用比较.中外医疗，2016，35（3）：149-151.
[12] 占国清，李芳，李刚.恩替卡韦治疗慢加急性乙型肝炎肝衰竭近期疗效评价. 实用肝脏病杂志，2013，16（1）：32-34.
[13] 庞月梅.恩替卡韦治疗慢性乙型肝炎患者疗效观察. 中国社区医师，2016，32（13）：66-68.
[14] 邬亚妙.合资、国产恩替卡韦治疗慢性乙型肝炎的最小成本分析. 药学实践杂志，2013，31（5）：388-389.
[15] 赖玺杰，杨益大，郑临，等.恩替卡韦分散片治疗HBeAg阳性慢性乙型肝炎的疗效观察.中华医院感染学杂志，2016，26（5）：988-990.

Domestic entecavir in treatment of patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.